Status:
RECRUITING
Long-term Alterations of Host-microbiome Interactions and Cardiovascular and Respiratory Diseases Progression After Pneumonia
Lead Sponsor:
Nantes University Hospital
Conditions:
Hospital Acquired Pneumonia (HAP)
Cardiovascular and Respiratory Disease
Eligibility:
All Genders
40-80 years
Phase:
NA
Brief Summary
The HOMI-LUNG - HAP study is part of the HOMI-LUNG project, funded by the Horizon Europe program. The "HOMI-LUNG" project is an international, interdisciplinary project that aims to better understand ...
Eligibility Criteria
Inclusion
- Group A (patients with acute cardiac disease)
- Male or female
- Age ≥ 40years old
- Hospitalized for acute coronary syndrome for less than 7 days.
- Informed consent from the patient
- Person insured under a health insurance scheme
- Group B (patients with chronic cardiovascular disease)
- Male or female,
- Age ≥ 40 years old
- Undergoing coronary artery by-pass surgery
- Hospitalized in intensive care unit for \> 12 hours
- Informed consent from the patient
- Person insured under a health insurance scheme
- Group C (patients at risk of CVRD without chronic cardiovascular disease)
- Male or female,
- Age ≥ 40 years old
- Familial high levels of cholesterol or triglycerides
- With no personal history of CVRD, with a recent negative cardiac exercise test (last test inferior to 12 months)
- Follow-up for lipid abnormalities at high risk of CVRD events
- Informed consent from the patient
- Person insured under a health insurance scheme
- Group D (patients with HAP)
- Male or female
- Age ≥ 40years old
- With one or more risk factors for CVD among:
- smoking, abnormal lipidic levels, high blood pressure, obesity, diabetes mellitus, chronic kidney disease
- Cured from mechanically ventilated HAP during the current hospitalization
- Informed consent from the patient or relatives
- Person insured under a health insurance scheme
Exclusion
- o Groups A, B, C and D
- Age \>80 years old
- Immunosuppression pre-existing to the index hospitalisation, defined as lymphopenia \< 500 elements/mm3, haematologic cancer, aplasia, chemotherapy/radiotherapy for cancer within 3 months prior to the inclusion, or anti-graft rejection drug.
- Pregnant women, breastfeeding women.
- Adults under guardianship or trusteeship.
- Low probability of survival at day 28.
- o Groups A, B, C
- Community-acquired pneumonia or Hospital-acquired pneumonia within the last year.
Key Trial Info
Start Date :
January 2 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2029
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06602934
Start Date
January 2 2025
End Date
May 1 2029
Last Update
January 17 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Angers University Hospital
Angers, France
2
Nantes University Hospital
Nantes, France
3
Rennes University Hospital
Rennes, France
4
Rouen University Hospital
Rouen, France